A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout
ConclusionSLC3037, a NLRP3 inhibitor blocking NEK7 binding to NLRP3, could be a novel agent against diseases associated with NLRP3 inflammasome activation such as gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Brain | Cardiology | Cardiovascular | Colchicine | Colcrys | Gout | Heart | Metabolic Syndrome | Neurology